Tag search results
Tags let us describe our content with keywords, making it easier to find what you're most interested in. Use the search box to look for tags, or explore our coverage with the lists below.
Pfizer, the country’s largest drugmaker, is creating a hybrid new drug company by combining its off-patent branded drug business, Upjohn, with generic pharmaceutical company Mylan. The two companies said Monday that they’ll ultimately spin off the combination of Mylan, a $10 billion company, with Upjohn, which sells household names from Viagra to cholesterol fighter Lipitor that have lost patent protection.
Mylan’s $465 million settlement of a U.S. case that claimed the drugmaker defrauded taxpayers by misclassifying its allergy-shot EpiPen product as a generic drug was finalized by the Justice Department.
Recent legislation in the U.S. Senate and in the Washington Legislature may eventually shine a brighter light on pricing practices.
CVS is now selling a rival, generic version of Mylan’s EpiPen at about a sixth of its price, just months after the maker of the life-saving allergy treatment was eviscerated before Congress because of its soaring cost to consumers.
Months after promised, Mylan launched a half-priced authorized generic of EpiPen, the lifesaving allergy injection that drew political ire for its dramatic price increases.
Senate Judiciary Chairman Charles Grassley says pharmaceutical company Mylan is declining to testify at his committee’s hearing next week on a settlement between the company and the Justice Department over its life-saving Epi-Pen.
Lawmakers were skeptical last week when Mylan chief executive Heather Bresch said that the company made only $100 in profit for a two-pack of EpiPens. During a House hearing, Bresch repeatedly referred to a poster board showing how little of the $608 list price trickled back to the company.
Outraged Republican and Democratic lawmakers on Wednesday grilled the head of pharmaceutical company Mylan about the significant cost increase of its lifesaving EpiPens and the profits for a company with sales in excess of $11 billion.
New York’s attorney general says his office is investigating Mylan Pharmaceuticals, which has been criticized for steep price increases for its emergency allergy treatment EpiPen.
The reality is that patients in other countries are charged less for health care services and drugs across the board, because their governments make it so.
As the mother of a kid with severe peanut/nut allergies I've been outraged and victimized by Mylan's shoddy jacking of EpiPen prices. In this column, Allan Sloan highlights the un-American behavior of Mylan and its fellow corporate deserters.
Mylan, the giant pharmaceutical company, has gotten tons of grief lately for jacking up the price of its lifesaving EpiPen. What you might not know is that Mylan moved it corporate base to the Netherlands last year to reduce its U.S. income taxes.
Mylan will start selling a cheaper version of its EpiPen after absorbing waves of criticism over a list price for the emergency allergy treatment that has grown to $608 for a two-pack, making it unaffordable for many patients.
The following editorial from the Sacramento Bee does not necessarily reflect the view of The Spokesman-Review's editorial board. It’s bad enough that the price of life-saving EpiPens has exploded from $94 in 2007 to more than $600 now.